Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.
Epistemonikos ID: 87442be988a581534ad6d31f56902efb70788c34
First added on: May 11, 2024